Standout Papers

Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH 2023 2026 2024240
  1. Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH (2023)
    Rohit Loomba, Arun J. Sanyal et al. New England Journal of Medicine

Immediate Impact

1 from Science/Nature 59 standout
Sub-graph 1 of 22

Citing Papers

Estimated Burden of Metabolic Dysfunction–Associated Steatotic Liver Disease in US Adults, 2020 to 2050
2025 Standout
Metabolic dysfunction-associated steatotic liver disease in adults
2025 Standout

Works of Robert J. Barish being referenced

Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
2023 Standout

Author Peers

Author Last Decade Papers Cites
Robert J. Barish 167 122 141 183 42 550
Jennifer Kwak 96 244 169 118 38 600
Daniela Constantinescu 228 129 291 68 55 648
James M. Woolfenden 62 250 109 63 43 612
Xiaofei Zhu 108 100 139 70 54 611
K.A. Lathrop 71 285 161 47 26 577
G.J. Duffy 49 163 240 36 31 565
J Fan 81 69 130 99 53 599
Assaf Moore 58 83 264 80 52 619
Valentina Brancato 16 213 129 65 39 525
Thomas Winkens 41 283 97 54 74 564

All Works

Loading papers...

Rankless by CCL
2026